Cyclo Therapeutics, Inc. (CYTH)
NASDAQ: CYTH · Real-Time Price · USD
0.928
-0.262 (-22.02%)
At close: Feb 10, 2025, 7:59 PM
0.910
-0.018 (-1.94%)
Pre-market: Feb 11, 2025, 7:31 AM EST
Cyclo Therapeutics Employees
Cyclo Therapeutics had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
$108,841
Profits / Employee
-$3,099,959
Market Cap
26.70M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
CYTH News
- 3 days ago - Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old) - Business Wire
- 27 days ago - Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025 - Business Wire
- 7 weeks ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders - PRNewsWire
- 2 months ago - Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio - GlobeNewsWire
- 3 months ago - Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 5 months ago - Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - Business Wire
- 6 months ago - CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH - Business Wire
- 6 months ago - Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries - Business Wire